United Therapeutics (NASDAQ:UTHR) CEO Sells $4,863,715.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, August 24th. The shares were sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $166,105,082.71. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Performance

Shares of UTHR opened at $527.91 on Friday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The company has a market capitalization of $22.64 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The firm has a 50-day simple moving average of $530.89 and a 200-day simple moving average of $538.86.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company posted $6.41 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics in the second quarter valued at $277,000. Cerity Partners LLC boosted its position in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.